Background
==========

In modern interventional therapy, percutaneous coronary intervention (PCI) is the main method of revascularization in patients with coronary heart disease. PCI can significantly improve the symptoms of myocardial ischemia and reduce the incidence of vascular events in patients with coronary heart disease \[[@b1-medscimonit-24-4154]\]. The incidence of perioperative myocardial injury (PMI), also known as myocardial infarction, did not substantially decreased despite technological advances and effective medical treatment \[[@b2-medscimonit-24-4154]\]. Many clinical studies have shown that PMI is a predictor of adverse clinical outcomes after PCI. According to the Global Working Group on Myocardial Infarction (ESC/ACC/AHA/EHS/WHO), one of the criteria for definition of myocardial infarction (MI) is serum biomarkers (specifically troponin) elevation. Cardiac troponins are sensitive and specific markers of myocardial necrosis \[[@b3-medscimonit-24-4154],[@b4-medscimonit-24-4154]\]. Previous cardiovascular magnetic resonance imaging studies showed that elevation of TnI after PCI indicates new irreversible myocardial injury \[[@b5-medscimonit-24-4154]\]. They were benefited from the sensitivity, specificity, and prognosis of acute coronary syndrome ACS compare with creatine kinase (CK) and creatine kinase-muscle-brain (CK-MB) \[[@b6-medscimonit-24-4154]--[@b9-medscimonit-24-4154]\]. Postoperative cTnI\> 1x the upper limit of normal (ULN) was interpreted as perioperative myocardial injury. Postoperative cTnI \>3×ULN was diagnosed as myocardial infarction after PCI in 2007, and postprocedural cTnI \>5×ULN, which was defined as PCI-related myocardial infarction in 2012 \[[@b10-medscimonit-24-4154], [@b11-medscimonit-24-4154]\].

Dyslipidemia is an independent risk factor for coronary heart disease. Clinical trials have shown that elevated LDL is linearly associated with coronary heart disease (CHD) \[[@b12-medscimonit-24-4154]\]. Cardiovascular events and mortality could be reduced by 20% to 50% by interventions to lower levels of LDL-C. Researchers have suggested that patients with low LDL-C have reduced risk of postoperative myocardial injury in eastern China \[[@b13-medscimonit-24-4154]\]. Although the lipid metabolism in urban and rural areas of southern China was reported to be associated with the special food culture, as well as genetic variants such as thalassemia, which may contribute to cardiovascular diseases in this area, little is known about whether the PCI patients with lower levels of LDL-C also have lower risk of PMI in southern China \[[@b14-medscimonit-24-4154],[@b15-medscimonit-24-4154]\]. In this study, we explored the connection between preprocedural LDL-C levels and PMI in patients following elective PCI in southern China.

Material and Methods
====================

Patient population
------------------

Eligibility screening was performed in patients undergoing coronary artery interventional therapy (PCI) at Meizhou People's Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University. CHD patients were eligible for inclusion if they exhibited: (1) stable angina, or unstable angina and received elective PCI surgery, and (2) there were no ST segment elevation or non-ST segment elevation acute myocardial infarctions in the 4 weeks before the intervention. The major exclusion criteria were: (1) the patient died after PCI or angiography failed, (2) incomplete data on lipid files for patients, and (3) patients treated with atheroablative, distal protection devices, or aspiration thrombectomy.

From September 2014 to September 2016, a total of 1942 patients without acute myocardial infarction in the past 4 weeks who attempted to undergo elective PCI at Meizhou People's Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University, were eligible for this study. The present study was performed in accordance with the ethics standards laid down in the updated version of the 1964 Declaration of Helsinki and was approved by Human Ethics Committees of Meizhou People's Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University, Guangdong province, China. All patients had signed informed consent.

Percutaneous coronary intervention
----------------------------------

The indications for PCI were based on recommendations from the ACC/AHA, and all of patients were operated on by experienced interventional cardiologists. Patients were treated with aspirin (100--300 mg/day) and clopidogrel (300--600 mg) at least 2 h before PCI. All patients accepted a bolus of ungraded heparin 5000 U or 70 U/kg just before surgery, and a bolus of 2000--3000 U was added when the procedure lasted more than 1 h. The interventional cardiologist could decide on vascular access and PCI type based on the patient's characteristics. The interventional cardiologist also could decide on total inflation times and inflation pressure of balloon, which is based on the technical properties of the balloon and the stent \[[@b16-medscimonit-24-4154]\]. All patients continuously received aspirin and clopidogrel daily after PCI. Glycoprotein IIb/IIIa inhibitors were used at the surgeon's discretion \[[@b12-medscimonit-24-4154]\].

ECG monitoring
--------------

The 12-lead electrocardiogram was recorded before and after PCI in all patients, and in case of occurrence of symptoms that were considered as postoperative ischemic events. All patients underwent continuous electrocardiographic monitoring after PCI.

Biochemical measurements
------------------------

Peripheral venous blood samples were collected before PCI for measuring lipid profiles. cTnI was detected before PCI and 24 h after PCI, as well as in the event of symptoms or signs that suggested myocardial ischemia. The LDL-C level was tested by selective solubilization method (AU5400 analyzer, Beckman Coulter, CA). cTnI was determined using the PATHFAST cTnI-II (cardiac troponin I) Test (Mitsubishi Chemical, Tokyo, Japan). The ULN was interpreted as the 99^th^ percentile of normal population with a total imprecision of \<10%. The ULN of this test was 0.02 ng/mL. The peak value of cTnI was statistically analyzed within 24 h.

Statistics
----------

The continuous variables and categorical variables are expressed as mean ± standard deviation, as percentage, or as frequencies with percentage, respectively. IBM SPSS Statistics 21.0 (IBM, Armonk, NY, USA) was used for all statistical analyses. Differences between groups based on LDL-C levels were analyzed using the χ^2^ test, Kruskal-Wallis test, or one-way ANOVA. The relationship of clinical parameters with postprocedural cTnI levels was tested by univariate linear regression analyses. The variables of P\<0.05 in univariate linear regression were used as variables in a stepwise multivariate linear model. Successful normalization of cTnI after log-transformation was analysis using the Kolmogorov-Smirnov test. The correlation between LDL-C levels and the occurrence of postprocedural cTnI elevations above various multiples of ULN were determined by logistic regression. Based on the Guidelines for the Prevention and Treatment of Chinese Adult Dyslipidemia 2016, LDL-C was considered as the cut-off point (\<70, 70--99, and ≥100 mg/dl). Additionally, variables were adjusted by the logistic model, and these variables were independently related to postprocedural cTnI levels. A probability value of *P*\<0.05 was considered significant for this study.

Results
=======

Clinical characteristics of the PCI patients
--------------------------------------------

The study flow chart is shown in [Figure 1](#f1-medscimonit-24-4154){ref-type="fig"}. Between September 2014 and September 2016, 1942 patients were enrolled in the study. [Table 1](#t1-medscimonit-24-4154){ref-type="table"} demonstrates the baseline characteristics and lipids level of the PCI patients according to the cut-off point in LDL-C levels. Patients with lower levels of LDL-C tended to be male with a higher proportion of current drinking. Patients with higher LDL-C were less often male, had a history of prior myocardial infarction, and were smokers, and more often had hypercholesterolemia, higher levels of triglycerides, total cholesterol, NT-proBNP, and hemoglobin. However, no significant differences were observed in age, diabetes, hypertension, family history of CAD, preprocedural cTnI, and other medications among groups.

Procedural characteristics of the patients are presented in [Table 2](#t2-medscimonit-24-4154){ref-type="table"} according to the cut-off point in LDL-C levels. We found no significant differences in target vessel, target lesion site, number of vascular lesions, and target lesion type expect target vessels among groups with different LDL-C levels.

Correlation analysis of LDL-C levels with postprocedural cTnI elevation
-----------------------------------------------------------------------

Peak postprocedural cTnI \>1×ULN, \>3×ULN, \>5×ULN, \>10×ULN, and \>15×ULN were detected in 1452 (74.8%), 1215 (62.6%), 1119(57.6%), 991 (51.0%), and 908 patients (46.8%), respectively. As shown in [Table 3](#t3-medscimonit-24-4154){ref-type="table"}, simple linear regression analysis was performed to study the correlation between postprocedural cTnI (log-transformed) and other variables. The results demonstrated preoperative LDL-C levels were significantly associated with postprocedural cTnI elevation (r=0.077, *P*=0.001), and sex, age, prior CABG, current smoking, systolic blood pressure, diastolic blood pressure, NT-proBNP, and hemoglobin were positively related to postprocedural cTnI. Most importantly, stepwise multivariable analysis revealed that postprocedural cTnI was significantly correlated with sex, prior myocardial infarction, CABG, diabetes, current smoking, systolic blood pressure, diastolic blood pressure, HDL-C, LDL-C, triglyceride, NT-proBNP, preprocedural cTnI, distal, and number of branch target vessels. However, diabetes and triglyceride were inversely correlated with postprocedural cTnI levels.

Logistic regression analyses for LDL-C levels with postoperative cTnI elevation risk
------------------------------------------------------------------------------------

As shown in [Table 4](#t4-medscimonit-24-4154){ref-type="table"}, the association of the LDL-C subgroup with risk of postprocedural cTnI elevation were determined by logistic regression. Univariate logistic regression showed that patients with preprocedural LDL-C of 70\~99 mg/dl were strongly correlated with lower risk of postprocedural cTnI elevation above 3×ULN up to \>20×ULN compared to those with preprocedural LDL-C ≥100 mg/dl. Moreover, patients with preprocedural LDL-C of \<70 mg/dl were more strongly associated with lower risk of postprocedural cTnI elevation above 3×ULN up to 20×ULN. In the adjusted logistic regression model, these associations were still present after adjusting for the all confounders according to the baseline of LDL-C levels ([Table 4](#t4-medscimonit-24-4154){ref-type="table"}).

Discussions
===========

To the best of our knowledge, this is the first study reporting the relationship of preprocedural LDL-C levels with PMI in patients undergoing PCI in southern China. The patients were carefully enrolled and sample size was robust in our study. The main finding of this study was that preprocedural LDL-C was correlated with postprocedural cTnI. Patients who had \<70 mg/dl or 70--99 mg/dl were strongly and independently associated with less risk of PMI. Therefore, the present study provides0 important information for lipid-lowering therapy in PCI patients.

High LDL-C level is not only a major cause of CAD, but also is related to the development of mature coronary plaques \[[@b17-medscimonit-24-4154]\]. There are many traditional risk factors for cardiovascular disease, such as smoking, diabetes, obesity, hypertension, and dyslipidemia. LDL-C is a well-established molecular risk factor. Li et al. found that the low preprocedural LDL-C levels were correlated with lower risk of PMI in PCI patients, and the risk of postprocedural cTnI elevation was increased by 12% to 20% due to increased 1-SD in LDL-C \[[@b13-medscimonit-24-4154]\]. Similarly, Buturak et al. also observed a direct connection between preprocedural LDL-C levels and PMI in PCI patient with stable angina pectoris \[[@b18-medscimonit-24-4154]\]. A cohort study that enrolled 302 consecutive patients reported that the ratios of LDL-C to high-density lipoprotein cholesterol (LDL-C/HDL-C) were significantly associated with PMI following elective PCI \[[@b19-medscimonit-24-4154]\]. Furthermore, in recent years, experiments have shown that LDL-C levels \<70 mg/dl were related to lower risk of cardiovascular events in secondary prevention populations. Thus, LDL-C plays an important role in secondary prevention and can reduce risk after PCI. According to the results of clinical studies, the hypothesis that "lower and better" in LDL-C level of patients with cardiovascular disease has been generally considered as optimal treatment \[[@b20-medscimonit-24-4154],[@b21-medscimonit-24-4154]\].

Numerous studies have shown that statins, by decreasing LDL-C, can significantly reduce the incidence of myocardial injury or infarction after PCI \[[@b22-medscimonit-24-4154]\]. Previous studies showed that statins have anti-inflammatory effect and anti-thrombotic properties, and improve endothelial function beyond merely decreasing LDL-C levels \[[@b23-medscimonit-24-4154]\]. The pleiotropic effects of statins are proved by clinical research *in vitro* and *in vivo*, and such effects were obviously beneficial in reducing myocardial injury during PCI. In addition, the effect of lowering LDL-C level on myocardial injury after PCI is mainly due to its effect on plaques.

LDL-C level plays an important role in plaque vulnerability, which is associated with a high risk of periprocedural myocardial injury in patients undergoing elective stent implantation \[[@b17-medscimonit-24-4154]\]. Clinical evidence showed that elevated LDL-C level is correlated with plaque characteristics and vulnerability, which were examined by intravascular ultrasound \[[@b24-medscimonit-24-4154],[@b25-medscimonit-24-4154]\], optical coherence tomography \[[@b26-medscimonit-24-4154]\], near-infrared spectroscopy \[[@b27-medscimonit-24-4154]\], and dual-source computed tomography \[[@b28-medscimonit-24-4154]\]. Vulnerable plaques have a large lipid core and a thin fibrous cap. Vulnerable plaques are prone to transfer, destruction, or exposure of thrombogenic material to the coronary flow, which may lead to thrombosis during and even following PCI. Therefore, intensive lipid-lowering therapy, especially LDL-C reduction, appears to slow plaque growth of minor lesions and reduce the occurrence of cardiovascular events in patients undergoing PCI \[[@b29-medscimonit-24-4154],[@b30-medscimonit-24-4154]\].

Our research also revealed that there are some independent factors connected with postoperative myocardial injury, such as sex, prior myocardial infarction, CABG, current smoking, systolic blood pressure, diastolic blood pressure, preprocedural cTnI, HDL-C, TC, triglyceride, NT-proBNP, and number of target vessels. Our findings may be important in developing instructions for health care and meditations for PMI patients with LDL-C undergoing PCI.

There are several limitations to this study. First, the presence of possible unmeasured variables might have confused the results, although we tried to adjust for known confounders. Secondly, the cTnI level was not tested continuously after PCI, but each patient received continuous electrocardiography. The cTnI level was additionally measured in the event of the occurrence of symptoms or signs suggestive of myocardial ischemia.

Conclusions
===========

In summary, PCI patients with low preprocedural LDL-C are independently correlated with a lower risk of PMI. Patients with preprocedural LDL-C of \<100 mg/dl had lower risk of periprocedural myocardial injury than those with preprocedural LDL-C of ≥100 mg/dl. Increased attention is needed to control LDL-C in southern China.
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###### 

Baseline clinical characteristics.

  Variable                      LDL-C at baseline   P value                             
  ----------------------------- ------------------- ----------------- ----------------- ---------
  Age, y                        65.38±9.98          65.50±10.47       63.26±10.85       \<0.001
  Male, n (%)                   122 (80.8%)         385 (78.7%)       972 (74.7%)       0.075
  Prior MI, n (%)               19 (12.6%)          38 (7.8%)         42 (3.2%)         0.000
  Prior CABG, n (%)             23 (15.2%)          53 (10.8%)        109 (8.4%)        0.013
  Diabetes, n (%)               40 (26.5%)          141 (28.8%)       325 (25.0%)       0.249
  Hypertension, n (%)           88 (58.3%)          267 (54.6%)       712 (54.7%)       0.692
  Hypercholesterolemia, n (%)   23 (15.1%)          92 (18.8%)        453 (34.8%)       0.000
  Current smoking, n (%)        61 (40.4%)          189 (38.7%)       490 (37.6%)       0.771
  Drinking                      15 (9.9%)           25 (5.1%)         53 (4.1%)         0.006
  HDL-C, mg/dl                  44.58±21.26         44.42±13.85       45.63±16.11       0.001
  LDL-C, mg/dl                  58.67±9.42          86.68±8.26        137.64±29.96      \<0.001
  TC, mg/dl                     122.38±144.15       395.02±5245.18    330.42±4314.50    \<0.001
  Triglyceride, mg/dl           136.73±29.47        162.17±145.62     181.88±125.02     \<0.001
  NT-proBNP, fmol/mL            1981.95±4407.46     2093.51±3787.81   1881.10±8562.90   0.001
  hemoglobin, mmol/L            124.41±24.07        132.86±44.24      136.72±17.83      \<0.001
  Preprocedural cTnI, ng/mL     4.47±9.20           4.92±9.51         5.05±9.99         0.254
  Postoperative cTnI, ng/mL     2.17±7.13           3.33±11.49        3.46±8.50         0.004
  Medications at study entry                                                            
   Statins, n (%)               141 (93.4%)         470 (96.1%)       1254 (96.3%)      0.215
   Aspirin, n (%)               136 (90.1%)         436 (89.2%)       1168 (89.7%)      0.927
   Clopidogrel, n (%)           135 (894%)          438 (89.6%)       1139 (87.5%)      0.421
   β-Blockers, n (%)            126 (83.4%)         384 (78.5%)       1116 (85.7%)      0.001
   Calcium blockers, n (%)      17 (11.3%)          63 (12.9%)        189 (14.5%)       0.424
   ARBs, n (%)                  126 (83.4%)         398 (81.4%)       1076 (82.6%)      0.779
   PPI                          120 (79.5%)         344 (70.3%)       871 (66.9%)       0.005

ARBs -- angiotensin receptor blockers; PPI -- proton pump inhibitors CABG -- coronary artery bypass graft; cTnI -- cardiac troponin I; HDL-C -- high-density lipoprotein cholesterol; LDL-C -- low-density lipoprotein cholesterol; TC -- total cholesterol; MI -- myocardial infarction; NT-proBNP -- N-terminal pro-brain natriuretic peptide; PCI -- percutaneous coronary intervention. Values are expressed as mean ± standard deviation.

###### 

Procedural characteristics.

  Variable                     LDL-C at baseline   P value                     
  ---------------------------- ------------------- ------------- ------------- ---------
  Target vessel                                                                
  LM                           19                  67            972           \<0.001
  LAD                          141                 467           42            \<0.001
  LCX                          114                 378           109           \<0.001
  RCA                          119                 407           325           \<0.001
  Lesion location                                                              
  Proximal                     120                 408           1082          0.499
  Middle                       135                 412           1094          0.069
  Distal                       96                  324           843           0.775
  Branch                       20                  55            190           0.183
  type B2/C                    93                  320           863           0.511
  Number of target vessel      2.47±0.79           2.56±0.79     2.56±0.75     0.160
  Number of stents implanted   1.37±0.52           1.35±0.56     1.39±0.61     0.437
  Total stent length, mm       34.66±16.68         35.62±17.55   36.27±19.32   0.966
  Bracket diameter             3.13±0.403          3.13±0.44     3.12±0.45     0.759

LM -- left main; LAD -- left anterior descending; LCX -- left circumflex; RCA -- right coronary artery; Values are expressed as n (%), mean ± standard deviation or median with interquartile range.

###### 

Analysis of factors associated with postoperative cTnI levels (log-transformed).

  Variable                        Simple regression   Multiple regression            
  ------------------------------- ------------------- --------------------- -------- ---------
  Sex (Male, Female)              0.35                0.09                  0.050    0.034
  Age, y                          0.25                0.219                          
  Prior MI, n (%)                 0.23                0.267                 0.051    0.03
  Prior CABG, n (%)               0.062               0.002                 0.059    0.013
  Diabetes, n (%)                 −0.032              0.081                 −0.052   0.014
  Hypertension, n (%)             0.970               0.322                          
  Hypercholesterolemia, n (%)     0.215               0.830                          
  Current smoking, n (%)          −0.087              \<0.001               −0.096   \<0.001
  Drinking                        0.011               0.542                          
  Systolic blood pressure mmHg    −0.144              \<0.001               0.096    0.001
  Diastolic blood pressure mmHg   −0.091              \<0.001               0.096    \<0.001
  HDL-C, mg/dl                    0.029               0.127                 0.075    0.001
  LDL-C, mg/dl                    0.070               \<0.001               0.082    \<0.001
  TC, mg/dl                       −0.015              0.390                          
  Triglyceride, mg/dl             −0.027              0.173                 −0.049   0.026
  NT-proBNP, mol/mL               0.073               \<0.001               0.089    \<0.001
  Platelets                       0.016               0.366                          
  hemoglobin, mmol/L              −0.038              0.044                          
  Preprocedural cTnI, ng/mL       0.199               \<0.001               0.276    \<0.001
  Target vessel                                                                      
   LM                             −0.021              0.248                          
   LAD                            0.001               0.977                          
   LCX                            0.260               0.363                          
   RCA                            −0.011              0.683                          
  Lesion location                                                                    
   Proximal                       0.01                0.599                          
   Middle                         −0.007              0.714                          
   Distal                         −0.035              0.074                 0.075    0.011
   Branch                         0.036               0.044                 0.065    0.002
   Number of target vessels       0.054               0.144                 0.087    \<0.001
   Number of type B2/C            −0.028              0.206                          
   Number of stents               0.004               0.839                          
   Stent diameter                 −0.013              0.472                          
   Total stent length             −0.022              0.235                          

CABG -- coronary artery bypass graft; cTnI -- cardiac troponin I; HDL-C -- high-density lipoprotein cholesterol; LDL-C -- lowdensity lipoprotein cholesterol; TC -- total cholesterol; MI -- myocardial infarction; NT-proBNP -- N-terminal pro-brain natriuretic peptide; SBP -- systolic blood pressure; DBP -- diastolic blood pressure; PCI -- percutaneous coronary intervention. Values are expressed as mean ± standard deviation, median with interquartile range or n (%).

###### 

Odds ratio (OR) for postprocedural cTnI elevation according to LDL-C levels.

                           No. of patients   Unadjusted model       Adjusted model                          
  ------------------------ ----------------- ---------------------- ---------------- ---------------------- -------
  Post-PCI cTnI \>1×ULN                                                                                     
   LDL-C ≤70 mg/dl         152               0.802 (0.551--1.167)   0.248            0.786 (0.520--1.189)   0.255
   LDL-C 70--99 mg/dl      489               0.863 (0.681--1.093)   0.233            0.776 (0.598--1.006)   0.055
   LDL-C ≥100 mg/dl        1302              Reference                               Reference              
  Post-PCI cTnI \>3×ULN                                                                                     
   LDL-C ≤70 mg/dl         152               0.651 (0.464--0.951)   0.013            0.641 (0.436--0.936)   0.021
   LDL-C 70--99 mg/dl      489               0.812 (0.656--1.006)   0.057            0.762 (0.603--0.965)   0.024
   LDL-C ≥100 mg/dl        1302              Reference                               Reference              
  Post-PCI cTnI \>5×ULN                                                                                     
   LDL-C ≤70 mg/dl         152               0.744 (0.530--1.043)   0.086            0.730 (0.502--1.063)   0.1
   LDL-C 70--99 mg/dl      489               0.795 (0.645--0.981)   0.032            0.732 (0.581--0.923    0.008
   LDL-C ≥100 mg/dl        1302              Reference                               Reference              
  Post-PCI cTnI \>10×ULN                                                                                    
   LDL-C ≤70 mg/dl         152               0.652 (0.464--0.916)   0.014            0.611 (0.416--0.896)   0.012
   LDL-C 70--99 mg/dl      489               0.747 (0.607--0.921)   0.006            0.671 (0531--0.84)     0.001
   LDL-C ≥100 mg/dl        1302              Reference                               Reference              
  Post-PCI cTnI \>15×ULN                                                                                    
   LDL-C ≤70 mg/dl         152               0.594 (0.419--0.843)   0.003            0.577 (0.363--0.797)   0.002
   LDL-C 70--99 mg/dl      489               0.807 (0.655--0.995)   0.045            0.733 (0.580--0.927)   0.009
   LDL-C ≥100 mg/dl        1302              Reference                               Reference              
  Post-PCI cTnI \>20×ULN                                                                                    
   LDL-C ≤70 mg/dl         152               0.545 (0.372--0.770)   0.001            0.476 (0.316--0.717)   0.000
   LDL-C 70--99 mg/dl      489               0.797 (0.645--0.984)   0.035            0.730 (0.576--0.924)   0.009
   LDL-C ≥100 mg/dl        1302              Reference                                                      

Adjusted model included sex, prior myocardial infarction, CABG, diabetes, current smoking, systolic blood pressure, diastolic blood pressure, HDL-C,LDL-C, Triglyceride, N-terminal pro-brain natriuretic peptide, preprocedural cTnI, number of target vessels, distal, branch. CABG -- coronary artery bypass graft; cTnI -- cardiac troponin I; HDL-C -- high-density lipoprotein cholesterol; LDL-C -- low-density lipoprotein cholesterol; SBP -- systolic blood pressure; DBP -- diastolic blood pressure; NT-proBNP -- N-terminal pro-brain natriuretic peptide; OR -- odds ratio; PCI -- percutaneous coronary intervention; ULN -- upper limit of normal.
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